Gentamicin

CHEMBL6067485 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
477.6 g/mol
LogP
-4.1
Phase
4

An aminoglycoside antibiotic used to treat serious bacterial infections caused by gram-negative organisms, including infections of the respiratory tract, urinary tract, bloodstream, and other sites. It works by binding to bacterial ribosomes and inhibiting protein synthesis, leading to bacterial cell death. Due to risks of kidney damage and hearing loss, blood levels and kidney function require careful monitoring during treatment.

น้ำหนักโมเลกุล

477.6000 g/mol

LogP

-4.10

TPSA

200.00 Ų

Lipinski RO5

ไม่ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC

InChI

InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3

Molecular Formula

C21H43N5O7

HBD / HBA

8 / 12

พันธะที่หมุนได้

7

อะตอมหนัก

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

An aminoglycoside antibiotic used to treat serious bacterial infections caused by gram-negative organisms, including infections of the respiratory tract, urinary tract, bloodstream, and other sites. It works by binding to bacterial ribosomes and inhibiting protein synthesis, leading to bacterial cell death. Due to risks of kidney damage and hearing loss, blood levels and kidney function require careful monitoring during treatment.

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

Yes, Gentamicin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6067485. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3467. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.